The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The goal for the project is the identification and optimization of anti-viral compounds.
The company has already embarked upon significant expansion in Turkey
Subscribe To Our Newsletter & Stay Updated
